Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $184.87

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have been given a consensus recommendation of “Buy” by the sixteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $184.8667.

Several analysts recently weighed in on the stock. Mizuho boosted their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group lifted their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. BTIG Research upped their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $136.60 on Tuesday. The firm has a 50 day moving average price of $100.32 and a two-hundred day moving average price of $85.47. The stock has a market cap of $1.62 billion, a P/E ratio of -51.94 and a beta of -0.30. Palvella Therapeutics has a 52-week low of $18.23 and a 52-week high of $151.18.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were purchased at an average price of $125.00 per share, with a total value of $500,000.00. Following the completion of the transaction, the director owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

A number of large investors have recently bought and sold shares of PVLA. Group One Trading LLC lifted its stake in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Archer Investment Corp bought a new stake in Palvella Therapeutics in the third quarter worth approximately $28,000. Russell Investments Group Ltd. bought a new stake in Palvella Therapeutics in the third quarter worth approximately $36,000. China Universal Asset Management Co. Ltd. acquired a new position in Palvella Therapeutics in the fourth quarter valued at approximately $167,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $37,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.